Skip to Content

RiaSTAP Approval History

FDA Approved: Yes (First approved January 16, 2009)
Brand name: RiaSTAP
Generic name: Fibrinogen Concentrate (Human)
Company: CSL Behring
Treatment for: Congenital Fibrinogen Deficiency

RiaSTAP (Fibrinogen Concentrate (Human)) is lyophilized fibrinogen for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Development History and FDA Approval Process for RiaSTAP

DateArticle
Jan 20, 2009Approval CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide